Background: Cardiorenal syndrome (CRS) encompasses conditions in which cardiac and renal disorders co-exist and are pathophysiologically related. The newest classification of CRS into seven etiologically and clinically distinct types for direct patient management purposes includes hemodynamic, uremic, vascular, neurohumoral, anemia- and/or iron metabolism-related, mineral metabolism-related and protein-energy wasting-related CRS. This classification also emphasizes the pathophysiologic pathways. The leading CRS category remains hemodynamic CRS, which is the most commonly encountered type in patient care settings and in which acute or chronic heart failure leads to renal impairment. Summary: This review focuses on selected therapeutic strategies for the clinical management of hemodynamic CRS. This is often characterized by an exceptionally high ratio of serum urea to creatinine concentrations. Loop diuretics, positive inotropic agents including dopamine and dobutamine, vasopressin antagonists including vasopressin receptor antagonists such as tolvaptan, nesiritide and angiotensin-neprilysin inhibitors are among the pharmacologic agents used. Additional therapies include ultrafiltration (UF) via hemofiltration or dialysis. The beneficial versus unfavorable effects of these therapies on cardiac decongestion versus renal blood flow may act in opposite directions. Some of the most interesting options for the outpatient setting that deserve revisiting include portable continuous dobutamine infusion, peritoneal dialysis and outpatient UF via hemodialysis or hemofiltration. Key Messages: The new clinically oriented CRS classification system is helpful in identifying therapeutic targets and offers a systematic approach to an optimal management algorithm with better understanding of etiologies. Most interventions including UF have not shown a favorable impact on outcomes. Outpatient portable dobutamine infusion is underutilized and not well studied. Revisiting traditional and novel strategies for outpatient management of CRS warrants clinical trials.

Keywords:
Heart failure, Ultrafiltration, Acute kidney injury, Cardiorenal syndrome, Chronic kidney disease, Dobutamine
1.
Ronco C, Haapio M, House AA, et al: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
2.
Hatamizadeh P, Fonarow GC, Budoff MJ, et al: Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 2013;9:99-111.
3.
McCullough PA, Kellum JA, Haase M, et al: Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013;182:82-98.
4.
Braam B, Joles JA, Danishwar AH, et al: Cardiorenal syndrome - current understanding and future perspectives. Nat Rev Nephrol 2014;10:48-55.
5.
Verbrugge FH, Grieten L, Mullens W: Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med 2014;4:176-188.
6.
Smith GL, Lichtman JH, Bracken MB, et al: Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-1996.
7.
Gigante A, Liberatori M, Gasperini ML, et al: Prevalence and clinical features of patients with the cardiorenal syndrome admitted to an internal medicine ward. Cardiorenal Med 2014;4:88-94.
8.
Clementi A, Virzi GM, Goh CY, et al: Cardiorenal syndrome type 4: a review. Cardiorenal Med 2013;3:63-70.
9.
Damman K, Navis G, Voors AA, et al: Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608.
10.
Virzi GM, Clementi A, Brocca A, et al: The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. Cardiorenal Med 2014;4:103-112.
11.
Scadding JG: Diagnosis: the clinician and the computer. Lancet 1967;2:877-882.
12.
Palazzuoli A, Ruocco G, Pellegrini M, et al: Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function. Cardiorenal Med 2014;4:257-268.
13.
Groenveld HF, Januzzi JL, Damman K, et al: Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
14.
Okonko DO, Mandal AK, Missouris CG, et al: Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241-1251.
15.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al: Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-668.
16.
Heine GH: Mineral metabolism in heart disease. Curr Opin Nephrol Hypertens 2015;24:310-316.
17.
Anker SD, Sharma R: The syndrome of cardiac cachexia. Int J Cardiol 2002;85:51-66.
18.
Fouque D, Kalantar-Zadeh K, Kopple J, et al: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391-398.
19.
Yancy CW, Jessup M, Bozkurt B, et al: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
20.
Abraham WT, Adams KF, Fonarow GC, et al: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
21.
Elkayam U, Tasissa G, Binanay C, et al: Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007;153:98-104.
22.
Cuffe MS, Califf RM, Adams KF Jr, et al: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547.
23.
McMurray JJ, Adamopoulos S, Anker SD, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
24.
Lindenfeld J, Albert NM, Boehmer JP, et al: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:e1-e194.
25.
Elkayam U, Ng TM, Hatamizadeh P, et al: Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008;117:200-205.
26.
Giamouzis G, Butler J, Starling RC, et al: Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010;16:922-930.
27.
Chen HH, Anstrom KJ, Givertz MM, et al: Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013;310:2533-2543.
28.
Husebye T, Eritsland J, Muller C, et al: Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 2013;15:565-572.
29.
Koster G, Wetterslev J, Gluud C, et al: Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2015;41:203-221.
30.
Bragadottir G, Redfors B, Ricksten SE: Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med 2013;41:2328-2335.
31.
Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
32.
Mebazaa A, Nieminen MS, Packer M, et al: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.
33.
Mebazaa A, Nieminen MS, Filippatos GS, et al: Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11:304-311.
34.
Schulz R, Rose J, Martin C, et al: Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993;88:684-695.
35.
Cohn JN, Goldstein SO, Greenberg BH, et al: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-1816.
36.
Hampton JR, van Veldhuisen DJ, Kleber FX, et al: Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-977.
37.
Bonios MJ, Terrovitis JV, Drakos SG, et al: Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 2012;159:225-229.
38.
Bock JS, Gottlieb SS: Cardiorenal syndrome: new perspectives. Circulation 2010;121:2592-2600.
39.
Francis GS, Siegel RM, Goldsmith SR, et al: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
40.
Rudy DW, Voelker JR, Greene PK, et al: Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991;115:360-366.
41.
Salvador DR, Rey NR, Ramos GC, et al: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005;3:CD003178.
42.
Felker GM, Lee KL, Bull DA, et al: Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
43.
Palazzuoli A, Pellegrini M, Ruocco G, et al: Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Crit Care 2014;18:R134.
44.
Allen LA, Turer AT, Dewald T, et al: Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol 2010;105:1794-1797.
45.
Wu MY, Chang NC, Su CL, et al: Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. J Crit Care 2014;29:2-9.
46.
Brater DC: Diuretic therapy. N Engl J Med 1998;339:387-395.
47.
Shah RV, McNulty S, O'Connor CM, et al: Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Am Heart J 2012;164:862-868.
48.
Chawla LS, Davison DL, Brasha-Mitchell E, et al: Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 2013;17:R207.
49.
Jenkins PG: Diuretic strategies in patients with acute heart failure. N Engl J Med 2011;364:2066; author reply 2069.
50.
Jaski BE, Ha J, Denys BG, et al: Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003;9:227-231.
51.
Costanzo MR, Guglin ME, Saltzberg MT, et al: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-683.
52.
Bart BA, Boyle A, Bank AJ, et al: Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043-2046.
53.
Bart BA, Goldsmith SR, Lee KL, et al: Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-2304.
54.
Marenzi G, Muratori M, Cosentino ER, et al: Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail 2014;20:9-17.
55.
Mentz RJ, Stevens SR, DeVore AD, et al: Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail 2015;3:97-107.
56.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2.
57.
Lu R, Muciño-Bermejo MJ, Ribeiro LC, et al: Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med 2015;5:145-156.
58.
Pannu N, Klarenbach S, Wiebe N, et al: Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008;299:793-805.
59.
Bagshaw SM, Berthiaume LR, Delaney A, et al: Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med 2008;36:610-617.
60.
Schneider AG, Bellomo R, Bagshaw SM, et al: Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Med 2013;39:987-997.
61.
Tolwani A: Continuous renal-replacement therapy for acute kidney injury. N Engl J Med 2012;367:2505-2514.
62.
Lins RL, Elseviers MM, Van der Niepen P, et al: Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant 2009;24:512-518.
63.
Wald R, Shariff SZ, Adhikari NK, et al: The association between renal replacement therapy modality and long-term outcomes among critically ill adults with acute kidney injury: a retrospective cohort study. Crit Care Med 2014;42:868-877.
64.
Lonnemann G, Floege J, Kliem V, et al: Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 2000;15:1189-1193.
65.
Kielstein JT, Kretschmer U, Ernst T, et al: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004;43:342-349.
66.
Schwenger V, Weigand MA, Hoffmann O, et al: Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012;16:R140.
67.
Marshall MR, Creamer JM, Foster M, et al: Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant 2011;26:2169-2175.
68.
Srisawat N, Lawsin L, Uchino S, et al: Cost of acute renal replacement therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study. Crit Care 2010;14:R46.
69.
Wilcox CS, Mitch WE, Kelly RA, et al: Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102:450-458.
70.
Elhassan EA, Schrier RW: Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens 2011;20:161-168.
71.
Travers B, O'Loughlin C, Murphy NF, et al: Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. J Card Fail 2007;13:128-132.
72.
Aliti GB, Rabelo ER, Clausell N, et al: Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med 2013;173:1058-1064.
73.
Smyth A, O'Donnell MJ, Yusuf S, et al: Sodium intake and renal outcomes: a systematic review. Am J Hypertens 2014;27:1277-1284.
74.
Schrier RW, Gross P, Gheorghiade M, et al: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.
75.
Gheorghiade M, Gattis WA, O'Connor CM, et al: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971.
76.
Konstam MA, Gheorghiade M, Burnett JC Jr, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
77.
Gheorghiade M, Konstam MA, Burnett JC Jr, et al: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-1343.
78.
Sackner-Bernstein JD, Kowalski M, Fox M, et al: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
79.
Chen HH, Sundt TM, Cook DJ, et al: Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 2007;116:I134-I138.
80.
Riter HG, Redfield MM, Burnett JC, et al: Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006;47:2334-2335.
81.
O'Connor CM, Starling RC, Hernandez AF, et al: Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
82.
Gottlieb SS, Stebbins A, Voors AA, et al: Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). J Am Coll Cardiol 2013;62:1177-1183.
83.
Voors AA, Dorhout B, van der Meer P: The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs 2013;22:1041-1047.
84.
McMurray JJ, Packer M, Desai AS, et al: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.